GNMSF:OTCMKTS
Genmab
274,50Â USD
0,00%
(0,00) 1G
20 lug, 11:45:33 GMT-4 · USD
search
Tutti i simboli
1G
5G
1M
6M
YTD
1A
5A
MAX
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli approfondimenti principali per GNMSF in corso…
Cap. mercato
18,37Â Mld
Vol. medio
112,00
Volume
0,00
Max 52 sett.
352,00Â USD
Min 52 sett.
216,31Â USD
Beta
0,77
Azioni in circolazione
62,35Â Mln
N. di dipendenti
3K
Cap. mercato
18,37Â Mld
Vol. medio
112,00
Volume
0,00
Max 52 sett.
352,00Â USD
Min 52 sett.
216,31Â USD
Beta
0,77
Azioni in circolazione
62,35Â Mln
N. di dipendenti
3K
Articoli giornalistici
Da fonti sul web
Ad-hoc-news.de
·
3 ore fa
Genmab stock trades steadily as investors weigh recent earnings and oncology pipeline momentum
Stock Titan
·
4 ore fa
Epcoritamab U.S. Lymphoma Trial Does Not Meet Survival Endpoint
Investing.com
·
1 giorno fa
TD Cowen upgrades Genmab stock rating on drug pipeline confidence
Profilo
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab Co., Ltd. in Suzhou, China. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US. Wikipedia
Informazioni su Genmab
I contenuti creati con l'AI potrebbero contenere errori. Scopri di più